â– LECTURE OVERVIEW: Organophosphate poisoning is a life-threatening toxidrome resulting from severe, uninhibited acetylcholinesterase inactivation that triggers massive cholinergic hyperstimulation.
â– MOLECULAR TOXICOLOGY & ACTIONS:
1. Phosphorylation of active site: Organophosphates (found in agricultural insecticides like parathion, malathion and nerve gases like sarin) bind covalently to the serine hydroxyl group of acetylcholinesterase (AChE), neutralizing the enzyme.
2. Acetylcholine Overdrive: Acetylcholine accumulates in synaptic clefts across muscarinic, nicotinic, and central nervous system synapses.
3. Cholinergic Excess (DUMBBELSS): Drives a massive cholinergic crisis: Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia, Emesis, Lacrimation, Salivation, and Sweating. Nicotinic accumulation causes muscle fasciculations, muscle fatigue, flaccid paralysis (diaphragm failure), and central respiratory depression.
4. Chemical Aging: Over hours, the covalent bond undergo dealkylation ('aging'), rendering the AChE chemical blockade completely permanent and irreversible.
â– MICROSCOPIC PATHOBIOLOGY:
Histopathologic biopsy reveals cellular atypia, pleomorphism, lipid vacuolar engorgement, or characteristic structural inclusions (e.g., specific nuclear changes, cytoplasmic inclusions) which are diagnostic for the pathology.
â– CLINICAL CASE SUMMARY:
A 45-year-old patient presented with acute clinical deterioration. Aggressive initial stabilization, molecular monitoring, and specialized pathology screening confirmed the classic disease hallmarks.
[HY-BOARD-1026]
🌟 Dynamic Clinical Key:
Management requires a rapid, dual-action antidote: Atropine (a competitive muscarinic blocker) to address life-threatening bradycardia and bronchospasm, and Pralidoxime (2-PAM), an oxime compound designed to dephosphorylate and regenerate active AChE. Crucially, Pralidoxime must be administered before AChE 'aging' occurs to be effective. Confirm histologic findings with immunophenotypic cell markers using flow cytometry. Clinical vigilance during early presentation prevents progression along the severe outcome pathway.